Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION via PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2019 · second_quarter · Q2
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Source: Senate LDA
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Protecting Consumer Access to Generic Drugs Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Orange Book Transparency Act of 2020
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Orange Book Transparency Act of 2020
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Further Extension of Continuing Appropriations Act, 2021
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Further Extension of Continuing Appropriations Act, 2021
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Payment Commission Data Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug STAR Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug STAR Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Drug STAR Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Pricing for the People Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Pricing for the People Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
BLOCKING Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
BLOCKING Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
CREATES Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
CREATES Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
FAST Generics Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
FAST Generics Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Pricing for the People Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Prescription Pricing for the People Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Lower Health Care Costs Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Lower Health Care Costs Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Phair Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Biologic Patent Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Biologic Patent Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Transparent Drug Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Transparent Drug Pricing Act of 2019
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Proposed Part D Rule and accompanying RFI. Issues related to Medicaid Provider Enrollment. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 1703, Medical Product Communications Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.1703 Medical Product Communications Act H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.3447, Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, accelerated generic approval, bio-similars.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 1703, Medical Product Communications Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.1703 Medical Product Communications Act H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.3447, Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, accelerated generic approval, bio-similars.
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Proposed Part D Rule and accompanying RFI. Issues related to Medicaid Provider Enrollment. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Prescription Drug Price Transparency Act
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Medical Product Communications Act of 2017
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 1703, Medical Product Communications Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.1703 Medical Product Communications Act H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.3447, Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, accelerated generic approval, bio-similars.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · Firm: PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION via PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2019 · first_quarter · Q1
Issues related to prescription drug coverage and pharmacy benefits. Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act
Issues related to prescription drug coverage and pharmacy benefits. Issues included in the Administrations drug pricing Blueprint. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market. Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act S.801/H.R. 1264: Payment Commission Data Act S. 64: Preserve Access to Affordable Generics and Biosimilars Act H.R. 938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act S. 340/H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R. 985: Fair Access for Safe and Timely (FAST) Generics Act S 659: Biologic Patent Transparency Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R. 1503: Orange Book Transparency Act
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses. H.R. 803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R.1034/S.640: Phair Pricing Act of 2019. H.R.1035: Prescription Drug Price Transparency Act. S. 476: C-THRU Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION via PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2018 · fourth_quarter · Q4
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION via PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2018 · third_quarter · Q3
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars.
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits. Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Part D Rule and accompanying RFI. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION via PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
2018 · second_quarter · Q2
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Proposed Part D Rule and accompanying RFI. Issues related to Medicaid Provider Enrollment. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues included in the Proposed Part D Rule and accompanying RFI and the Administrations Blueprint on drug pricing RFI . Issues related to Medicaid Provider Enrollment. Issues related to prescription drug abuse. Issues related to the Medicare Coverage Gap Discount. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R. 1703, Medical Product Communications Act H.R. 2026, Pharmaceutical Information Exchange Act H.R.2051, FAST Generics Act H.R.2212/S.974, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 H.R.1703 Medical Product Communications Act H.R.2077 Restoring the Patient's Voice Act of 2017 S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.3528/S.2460, The Every Prescription Carried Safely Act H.R.3447, Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, accelerated generic approval, bio-similars.
Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, mail-service pharmacy and safe harbors related to manufacturer rebates. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare and Medicaid. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). Issues related to Medicaid Provider Enrollment. Issues related to the Medicare Coverage Gap Discount. H.R.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug ActH.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies ActH.R.3528/S.2460, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 H.R.5958, Fair Pricing Act of 2018 H.R.5343, Prescription Transparency Act of 2018
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE